{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-008113","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2024-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.260889+00:00","generated_at":"2026-06-05T05:48:28.734648+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Prime Medicine reports FY2023 net loss of $198.1M; eyes IND/CTA for CGD in 1H 2024","bullets":["Net loss widened to $198.1M in FY2023 ($121.8M in FY2022); R&D expenses $147.9M up from $86.7M.","Cash, equivalents, investments, restricted cash $135.2M at Dec 31, 2023, vs $307.4M year earlier.","Closed upsized public offering in Feb 2024, gross proceeds ~$161.0M at $6.25 per share.","Expects to file IND/CTA for PM359 (CGD) in 1H 2024; initial clinical data anticipated in 2025.","Received Orphan Drug Designation for PM359; $15M CF Foundation funding for CF Prime Editors."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-008113","json":"https://secwatch.observer/filing/0001628280-24-008113.json","markdown":"https://secwatch.observer/filing/0001628280-24-008113.md","text":"https://secwatch.observer/filing/0001628280-24-008113.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024008113/0001628280-24-008113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024008113/prme-20240301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T05:48:28.734648+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6e5aede81c88e0aca65f83c60357d7c7efc7d45d","claim":"Prime Medicine, Inc. reported the full year ended December 31, 2023 results: net income $198.1 million.","evidence_excerpt":"Net loss was $198.1 million for the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024008113/0001628280-24-008113-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Net income","value":"$198.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}